Evidence map›Paper›PMID 35836512›Full record

ArticleTranslational cancer research2022

Increase of CD3

Ziyang Huang, Binbin Chen, Yixin Ling, Yangya Pan, Songfu Jiang, Shenghui Zhang, Kang Yu, Yixiang Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ziyang Huang *Department of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Binbin Chen *Department of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yixin LingDepartment of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yangya PanDepartment of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Songfu JiangDepartment of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shenghui ZhangDepartment of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Kang YuDepartment of Hematology, Wenzhou Key Laboratory of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yixiang HanCentral Laboratory, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The T-cell non-Hodgkin's lymphoma (T-NHL) patients with bone marrow (BM) invasion have a poor prognosis. Although BM biopsy is still a confirmed diagnosis method, the low sensitivity restricts its use to detect the minimal BM invasion. It is of great clinical significance to establish a rapid and highly sensitive method to evaluate BM invasion. Methods: We conducted a retrospective study of 85 patients with new diagnosed T-NHL patients enrolled in our institute. The bone marrow mononuclear cells (BMMNCs) cells were isolated, stained with different combinations of antibody and subjected to flow cytometry analysis. Results: We found that CD3 Conclusions: Our study revealed the percentage of CD3

Indexed as

CD3+CD7− T cellsprognostic predictorT-cell non-Hodgkin’s lymphoma (T-NHL)

Identifiers

PMID35836512
PMCPMC9273714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.